Palvella Therapeutics (PVLA)
What the price implies
A reverse DCF: instead of guessing a fair value, it asks what growth today's price already assumes. How it works.
Fundamental grade
Five factors scored 1 to 9 from PVLA's latest numbers, weighted into one grade. It describes the business, not whether the stock is a buy.
Key numbers
Results from SEC filings
Fiscal years, from Palvella Therapeutics's 10-K filings. Ten years of the full income statement, balance sheet and cash flow.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $28M | $25M | $39M | — | — |
| Net income | -$46M | -$33M | $19M | -$17M | -$42M |
| Free cash flow | -$9M | -$61M | -$14M | — | — |
| EPS (diluted) | -$0.71 | -$0.45 | $2.17 | -$7.83 | -$3.71 |
| Operating margin | -185.5% | -170.7% | -30.7% | — | — |
Superinvestors who own PVLA
From each investor's latest 13F filing (what a 13F shows). 3 of the investors we track hold it.
| Investor | Last quarter | Value | % of portfolio | Quarter |
|---|---|---|---|---|
| PRIMECAP Management PRIMECAP Management Co |
Added | $39M | 0.02% | Q2 2026 |
| Hersh Cohen ClearBridge Investments |
Trimmed | $9M | 0.01% | Q2 2026 |
| Cliff Asness AQR Capital Management |
New position | $353,932 | 0.0% | Q2 2026 |
Insider buying
Open-market purchases by Palvella Therapeutics's executives and directors in the last 12 months, from SEC Form 4 filings. What insider buying tells you.
| Date | Insider | Shares | Price | Value |
|---|---|---|---|---|
| Feb 27, 2026 | Elaine J Heron |
2,400 | $125.00 | $300,000 |
| Feb 27, 2026 | George M Jenkins |
4,000 | $125.00 | $500,000 |
Get an alert at your buy price
Pick the price you'd be interested at. We'll email you when PVLA trades at or below it.
New accounts get 7 days of Pro, price alerts included. No card needed.
In the full deep dive
Questions
Are Palvella Therapeutics insiders buying the stock?
2 open-market insider purchases of PVLA in the last 12 months, from SEC Form 4 filings.
Which superinvestors own Palvella Therapeutics?
3 of the superinvestors Investingly tracks hold PVLA in their latest 13F, including PRIMECAP Management, Hersh Cohen, Cliff Asness.
Companies like Palvella Therapeutics
All Healthcare stocks · Biotechnology stocks · Stock lists
Prices and ratios as of Oct 11, 2026; statements from SEC filings. Information only, not investment advice. Superinvestor holdings come from 13F filings, which are filed up to 45 days after each quarter ends.